A review of the first year of Medicare coverage of erythropoietin.

Griffiths, RI; Powe, NR; Greer, J; de Lissovoy, G; Anderson, GF; Whelton, PK; Watson, AJ; Eggers, PW

Abstract:

Recombinant human erythropoietin (rHuEPO) is a new drug for treating anemia associated with end stage renal disease (ESRD). In a study of rHuEPO diffusion, costs, and effectiveness, we analyze ESRD program data and all claims submitted to Medicare for reimbursement of rHuEPO administered to ESRD dialysis patients. Access to rHuEPO was rapid and extensive during the first year of Medicare coverage. Dosing of rHuEPO and achieved hematocrit were lower than expected based on the results of clinic...

Expand abstract

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Griffiths, R. I., Powe, N. R., Greer, J., de Lissovoy, G., Anderson, G. F., Whelton, P. K., Watson, A. J., & Eggers, P. W. (1994). A review of the first year of Medicare coverage of erythropoietin. Health Care Financing Review, 15(3), 83–102.

MLA Style

Griffiths, R. I., et al. “A Review of the First Year of Medicare Coverage of Erythropoietin.” Health Care Financing Review, vol. 15, no. 3, 1994, pp. 83–102.

Chicago Style

Griffiths, RI, NR Powe, J Greer, G de Lissovoy, GF Anderson, PK Whelton, AJ Watson, and PW Eggers. 1994. “A Review of the First Year of Medicare Coverage of Erythropoietin.” Health Care Financing Review 15 (3): 83–102.
Tweet
Print